Paul Perreault, CSL Behring CEO
CSL lands FDA approval for hemophilia B gene therapy, sets $3.5M list price
The FDA has approved the world’s first gene therapy for hemophilia B, ushering into the market a treatment that’s historic in both what it promises …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
